Jiaoze
+86-21-37318802
[email protected]
Sitemap |  RSS |  XML
English English
  • English English
  • Home
  • About Us
    • Company Profile
    • Development History
    • Corporate Culture
  • Products
    • Intermediates And APIs
      • Intermediate
      • Active Pharmaceutical Ingredient
    • Veterinary Drug Service
    • Cosmetics Ingredients
  • News
    • Industry News
    • Company News
  • R&D Services
  • Send Inquiry
  • Contact Us
Send Inquiry
Home Send Inquiry

Product Categories

  • Intermediates And APIs

    • Intermediate
    • Active Pharmaceutical Ingredient
  • Veterinary Drug Service

  • Cosmetics Ingredients

New Products
  • Shikimic Acid CAS 138-59-0
    Shikimic Acid CAS 138-59-0
  • (R)-3-Piperidinamine dihydrochloride CAS 334618-23-4
    (R)-3-Piperidinamine dihydrochloride CAS 334618-23-4
  • Creatine monohydrate CAS 6020-87-7
    Creatine monohydrate CAS 6020-87-7
  • Tetramethyluric acid CAS 2309-49-1 HPLC 60%
    Tetramethyluric acid CAS 2309-49-1 HPLC 60%
  • Berberine hydrochloride CAS 633-65-8
    Berberine hydrochloride CAS 633-65-8
All new products

Send Inquiry

Verify Code
Links:

    Contact Us

    • Address: No.688 Qiushi Road, Jinshan Wei Town, Shanghai, China
    • Phone: +86-21-37318802
    • E-mail: [email protected]

    Inquiry For Price list

    For inquiries about our products or pricelist, please leave your email to us and we will be in touch within 24 hours.

    Latest News

    • CDMO Small Molecule Innovations: Can AI-Driven Crystallization Design Replace Traditional Methods?
      CDMO Small Molecule Innovations: Can AI-Driven Crystallization Design Replace Traditional Methods? 2025/06/04

      Crystallization remains a critical step in small molecule drug development—impacting purity, bioavailability, and manufacturability. In 2025, CDMOs are increasingly exploring AI-driven crystallization design as a transformative alternative to traditional trial-and-error methods.

    • Small Molecule vs Biologics CDMO Services: Why 78% of Pharma Firms Maintain Dual Partnerships?
      Small Molecule vs Biologics CDMO Services: Why 78% of Pharma Firms Maintain Dual Partnerships? 2025/05/15

      As the pharmaceutical landscape grows more complex, a striking trend has emerged in 2024: 78% of pharma companies now maintain partnerships with both small molecule and biologics-focused CDMOs. But what’s driving this dual engagement strategy?

    Copyright © 2024 Shanghai Jiaoze Industrial Co., Ltd. - All Rights Reserved
    • Links
    • Sitemap
    • RSS
    • XML
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial